1-羟基-3-甲基环己烷甲酰胺 | 101252-18-0

• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 1-羟基-3-甲基环己烷甲酰胺
• 英文名称: 1-hydroxy-3-methyl-cyclohexanecarboxylic acid amide
• 英文别名: 1-Hydroxy-3-methyl-cyclohexancarbonsaeure-amid；1-Hydroxy-3-methylcyclohexylcarboxamid；Cyclohexanecarboxamide, 1-hydroxy-3-methyl-；1-hydroxy-3-methylcyclohexane-1-carboxamide
• CAS: 101252-18-0
• 化学式: C₈H₁₅NO₂
• 分子量: 157.213
• InChiKey: WBNMRVWGINCTLJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.88
• 拓扑面积：
  63.3
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  1-羟基-3-甲基环己烷甲酰胺 在 硫酸 作用下， 生成 1-hydroxy-3-methylcyclohexanecarboxylic acid
  参考文献：
  名称：

  Effects of cosmonaut vestibular training on vestibular function prior to spaceflight

  摘要：

  The purpose of this study was to quantify the effects of repetitive Coriolis and cross-coupled stimulations, similar to the vestibular training the cosmonauts are exposed to prior to their spaceflight, on vestibular function in control subjects on Earth. Ten volunteers were passively rotated in yaw on a rotating chair while executing standardized pitch head-and-trunk movements. The chair stopped to change direction after 12 head-and-trunk movements were made. The runs were grouped in sessions of ten,which were repeated daily for 10 days. The severity of motion sickness was assessed by subjective judgment and measurements of skin pallor and salivary total protein concentration, and nystagmus was recorded. The severity of motion sickness and nystagmus decreased during cosmonaut vestibular training (CVT). One month after the end of CVT, nystagmus responses were still about 20-30% lower than control values. These results indicate that CVT induces a habituation of vestibular responses. One important implication of this experiment concerns space studies on cosmonauts who are exposed to such vestibular training prior to their spaceflight.

  DOI：

  10.1007/s004210100494
• 作为产物：
  描述：

  1-hydroxy-3-methyl-cyclohexanecarbonitrile 在 硫酸 作用下， 生成 1-羟基-3-甲基环己烷甲酰胺
  参考文献：
  名称：

  Effects of cosmonaut vestibular training on vestibular function prior to spaceflight

  摘要：

  The purpose of this study was to quantify the effects of repetitive Coriolis and cross-coupled stimulations, similar to the vestibular training the cosmonauts are exposed to prior to their spaceflight, on vestibular function in control subjects on Earth. Ten volunteers were passively rotated in yaw on a rotating chair while executing standardized pitch head-and-trunk movements. The chair stopped to change direction after 12 head-and-trunk movements were made. The runs were grouped in sessions of ten,which were repeated daily for 10 days. The severity of motion sickness was assessed by subjective judgment and measurements of skin pallor and salivary total protein concentration, and nystagmus was recorded. The severity of motion sickness and nystagmus decreased during cosmonaut vestibular training (CVT). One month after the end of CVT, nystagmus responses were still about 20-30% lower than control values. These results indicate that CVT induces a habituation of vestibular responses. One important implication of this experiment concerns space studies on cosmonauts who are exposed to such vestibular training prior to their spaceflight.

  DOI：

  10.1007/s004210100494

文献信息

• NOVEL INDOLE DERIVATIVES AND THEIR USE IN NEURODEGENERATIVE DISEASES
  申请人：Merck Patent GmbH

  公开号：US20160168090A1

  公开（公告）日：2016-06-16

  The present invention relates to indole compounds, and pharmaceutically acceptable compositions thereof, useful as antagonists of P2X7, and for the treatment of P2X7-related disorders.

  本发明涉及吲哚化合物及其药用可接受的组合物，用作P2X7拮抗剂，用于治疗与P2X7相关的疾病。
• [EN] INDOLIZINE DERIVATIVES WHICH ARE APPLICABLE TO NEURODEGENERATIVE DISEASES<br/>[FR] DÉRIVÉS D'INDOLIZINE POUVANT ÊTRE EMPLOYÉS DANS DES MALADIES NEURODÉGÉNÉRATIVES
  申请人：MERCK PATENT GMBH

  公开号：WO2016019228A1

  公开（公告）日：2016-02-04

  The present invention relates to indolizine compounds, and pharmaceutically acceptable compositions thereof, useful as antagonists of P2X7, and for the treatment of P2X7-related disorders.

  本发明涉及吲哚啉化合物及其药学上可接受的组合物，用作P2X7拮抗剂，用于治疗与P2X7相关的疾病。
• Novel Compounds 679
  申请人：Guile Simon David

  公开号：US20080234319A1

  公开（公告）日：2008-09-25

  The invention provides compounds of formula (I), processes for their preparation, pharmaceutical compositions containing them, a process for preparing the pharmaceutical compositions, and their use in therapy, wherein R 1 , R 2 , R 3 and n are as defined in the specification

  该发明提供了式（I）的化合物，其制备方法，含有它们的药物组合物，制备药物组合物的方法，以及它们在治疗中的应用，其中R1、R2、R3和n如规范中定义。
• [EN] NOVEL QUINOLINE DERIVATIVES AND THEIR USE IN NEURODEGENERATIVE DISEASES<br/>[FR] NOUVEAUX DÉRIVÉS DE QUINOLÉINE ET LEUR UTILISATION DANS DES MALADIES NEURODÉGÉNÉRATIVES
  申请人：MERCK PATENT GMBH

  公开号：WO2015187905A1

  公开（公告）日：2015-12-10

  The present invention relates to quinoline compounds, and pharmaceutically acceptable compositions thereof, useful as antagonists of P2X7, and for the treatment of P2X7-related disorders.

  本发明涉及喹啉化合物及其药用可接受的组合物，用作P2X7的拮抗剂，用于治疗与P2X7相关的疾病。
• NOVEL INDOLIZINE DERIVATIVES AND THEIR USE IN NEURODEGENERATIVE DISEASES
  申请人：Merck Patent GmbH

  公开号：US20160031879A1

  公开（公告）日：2016-02-04

  The present invention relates to indolizine compounds, and pharmaceutically acceptable compositions thereof, useful as antagonists of P2X7, and for the treatment of P2X7-related disorders.

  本发明涉及吲哚啉化合物及其药学上可接受的组成物，用作P2X7拮抗剂，并用于治疗与P2X7相关的疾病。